New hepatitis c drug shows promise in early safety trial
NCT ID NCT00591214
First seen Jan 06, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This early-stage study tested a single dose of the experimental drug MP-424 in 10 people with chronic hepatitis C (genotype 1b). The main goals were to check the drug's safety and how it behaves in the body. Researchers also measured how the drug affected hepatitis C virus levels over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
Conditions
Explore the condition pages connected to this study.